Oral Thin Films Market Size (2024 - 2029)

The Oral Thin Films Market is projected to experience significant growth during the forecast period, driven by the increasing prevalence of target diseases and the advantages of this drug delivery system. The market's expansion is supported by the growing demand for effective treatments for conditions such as schizophrenia, migraine, and Parkinson's disease, which have been exacerbated by the COVID-19 pandemic. Oral thin films offer benefits like dosage flexibility, ease of administration, and rapid onset of effects, making them particularly appealing for patients with specific needs. Despite potential technical limitations, the market is expected to grow as companies continue to innovate and expand their product offerings.

Market Size of Oral Thin Films Industry

Oral Thin Films Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 3.01 Billion
Market Size (2029) USD 4.75 Billion
CAGR (2024 - 2029) 9.56 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Oral Thin Films Market Major Players

*Disclaimer: Major Players sorted in no particular order

Oral Thin Films Market Analysis

The Oral Thin Films Market size is estimated at USD 3.01 billion in 2024, and is expected to reach USD 4.75 billion by 2029, growing at a CAGR of 9.56% during the forecast period (2024-2029).

The growing burden of target diseases and the advantages associated with thin films are the primary drivers for the oral thin films market. For instance, in August 2023, an article published in the Frontiers in Molecular Neuroscience mentioned that more than 10.0 million people were living with Parkinson's disease globally. Additionally, in December 2022, the Parkinson's Foundation reported that the new study represented a 50% higher incidence of Parkinson's disease in the United States, with 90,000 diagnoses each year as compared to the earlier year's estimates of 60,000 annual diagnoses. Moreover, the risk of Parkinson's disease increases with age; thus, the rising aging population worldwide is also expected to impact the market positively. Furthermore, it is likely that by 2030, there will be an increase of 1.2 million people who have Parkinson's disease. Oral thin films are considered one of the most effective treatments for Parkinson's disease. Therefore, the increasing prevalence of Parkinson's disease is anticipated to propel the demand for oral thins, thereby surging market growth over the coming years.

Drug delivery via oral thin films offers several advantages, which are the major factors driving market growth. For instance, in July 2023, an article published in the Journal of Pharmaceuticals mentioned various advantages of oral thin films used for mental disorders, such as faster disintegration and dissolving ability in the oral cavity, quicker onset action through oral mucosa, and flexible packaging, which facilitates transportation and storage and accuracy in the administration of dose and easy swallowing. They directly cause drugs to enter the circulatory system through oral and sublingual absorption. This prevents the medication from being exposed to the harsh conditions of the stomach by allowing this drug delivery system to deliver a more significant proportion of the active compound per dose. Thus, due to the abovementioned factors, the market studied is expected to grow during the forecast period.

To cater to the growth in demand, various companies are developing oral thin films to expand their portfolio. For instance, in September 2023, Gensco Pharma, in collaboration with IntelGenx, launched RizaFilm, an oral dissolvable film formulation of rizatriptan available for treating acute migraine. Similarly, in May 2022, Rapid Dose Therapeutics announced agreements to accelerate the development and commercialization of its QuickStripVax orally dissolvable film. The agreements resulted in Oakland Health, operating as RD Therapeutics, taking a 5.0% stake in a newly created RDT subsidiary that would be granted the exclusive worldwide license to sell products derived from the IP behind the QuickStripVax. Such product launches are expected to boost market growth over the forecast period.

On the other hand, the technical limitations of oral thin films are likely to impede market growth for a short period over the coming years.

Oral Thin Film Industry Segmentation

As per the scope, oral thin films (OTF) are thin, flexible films targeted for drug delivery. The thin films are taken orally and dissolve immediately in the mouth or are applied to the mucosa. For transmucosal films, the active substance enters the bloodstream directly via the oral mucosa without first passing through the gastrointestinal tract.

The oral thin films market is segmented by product, disease indication, distribution channel, and geography. By product, the market is segmented into sublingual film and other products. By disease indication, the market is segmented into opioid dependence, nausea and vomiting, and other disease indications. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and other distribution channels. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. For each segment, the market size is provided in terms of value (USD).

By Product
Sublingual Film
Other Products
By Disease Indication
Opioid Dependence
Nausea and Vomiting
Other Disease Indications
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Oral Thin Films Market Size Summary

The oral thin films market is poised for significant growth, driven by the increasing prevalence of target diseases and the inherent advantages of thin film drug delivery systems. These films offer benefits such as dosage flexibility, ease of administration, and rapid onset of effects, making them particularly useful for conditions requiring urgent intervention. The market has seen a surge in demand due to the COVID-19 pandemic, as oral thin films proved effective in treating patients with schizophrenia and migraine, who were at higher risk during the outbreak. The aging global population and the rising incidence of Parkinson's disease further contribute to the market's expansion, as oral thin films are recognized as effective treatments for these conditions. The market is characterized by ongoing research and development, strategic partnerships, and product launches, which are expected to propel growth during the forecast period.

North America is anticipated to dominate the oral thin films market, supported by a high concentration of market players, numerous product launches, and a growing number of cases of target diseases. The region's market growth is further bolstered by clinical trials and regulatory approvals, such as the FDA's clearance of new oral thin film products. The competitive landscape is moderately fragmented, with key players like Aquestive Therapeutics, IntelGenx Corp., and ZIM Laboratories actively engaging in product development to enhance their market share. Despite technical limitations, the market's growth trajectory remains positive, driven by the continuous innovation and strategic initiatives undertaken by industry participants.

Explore More

Oral Thin Films Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Burden of Target Diseases

      2. 1.2.2 Advantages Associated with Oral Thin Films

    3. 1.3 Market Restraints

      1. 1.3.1 Technical Limitations of Oral Thin Films

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Product

      1. 2.1.1 Sublingual Film

      2. 2.1.2 Other Products

    2. 2.2 By Disease Indication

      1. 2.2.1 Opioid Dependence

      2. 2.2.2 Nausea and Vomiting

      3. 2.2.3 Other Disease Indications

    3. 2.3 By Distribution Channel

      1. 2.3.1 Hospital Pharmacies

      2. 2.3.2 Retail Pharmacies

      3. 2.3.3 Other Distribution Channels

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Oral Thin Films Market Size FAQs

The Oral Thin Films Market size is expected to reach USD 3.01 billion in 2024 and grow at a CAGR of 9.56% to reach USD 4.75 billion by 2029.

In 2024, the Oral Thin Films Market size is expected to reach USD 3.01 billion.

Oral Thin Films Market Size & Share Analysis - Growth Trends & Forecasts (2024-2029) (2024 - 2029)